Hims & Hers Health, Inc.
NYSE:HIMSMedical - Equipment & Services
+$1.11 today
- Market cap
- $3.85B
- Beta
- 2.40
- P/E (TTM)
- -569.3
- EPS (TTM)
- -$0.06
Volume 9.53M
Average 26.18M
HIMS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Hims & Hers Health, Inc.NYSE: HIMS
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $69.39M rose 71.0% year over year, ahead of the +19.1% change in trailing-twelve-month research & development. Over 3 fiscal years it compounded at +72.2% a year.
Context
- Research & development amounted to 6.4% of revenue in FY2025, up 1.0 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +71.0% holds above the trailing-twelve-month pace of +19.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 149.3M USD
- Year-over-year change
- +89.4%
- 4-year CAGR
- +60.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 149.3M | +89.4% |
| FY2024 | 2024-12-31 | 78.82M | +63.4% |
| FY2023 | 2023-12-31 | 48.23M | +65.0% |
| FY2022 | 2022-12-31 | 29.24M | +30.6% |
| FY2021 | 2021-12-31 | 22.38M | — |
Research & Development vs competitors
How HIMS compares with its peers on the latest reported figures
- HIMS's LTM Sep 2026 research & development of $157.29M is the 2nd highest of the 10 companies compared; the peer median is $7.36M.
- Its year-over-year change of +19.1% is the highest of 7, against a peer median of -16.4%.
- Research & development amounts to 5.5% of revenue for HIMS, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $180M | — | — | 1.2% | |
| LTM Sep 2026 | $157.29M | +19.1% | +72.2% | 5.5% | |
| LTM Jun 2026 | $95M | -7.3% | -8.1% | 2.3% | |
| LTM Mar 2026 | $58.5M | -0.3% | +1.2% | 2.8% | |
| LTM Mar 2026 | $7.53M | -25.4% | +35.2% | 3.4% | |
| LTM Mar 2026 | $7.36M | +4.8% | +1.6% | 2.1% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Feb 2026 | $0 | -100.0% | +4.1% | 0.0% | |
| Peer median (excluding HIMS) | $7.36M | -16.4% | +1.6% | 1.2% | |
Competitors are the stored peer set for HIMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 271.88M | 526.92M | 872M | 1.48B | 2.35B |
| Cost of Revenue | 67.38M | 118.19M | 157.05M | 303.38M | 614.26M |
| Gross Profit | 204.49M | 408.72M | 714.95M | 1.17B | 1.73B |
| Gross Margin | 75.2% | 77.6% | 82.0% | 79.5% | 73.8% |
| Research & Development | 22.38M | 29.24M | 48.23M | 78.82M | 149.3M |
| Selling, General & Admin | 249.56M | 370.78M | 576.32M | 846.61M | 1.19B |
| Operating Expenses | 319.54M | 477.42M | 744.4M | 1.11B | 1.63B |
| Depreciation & Amortization | 4.08M | 7.47M | 9.52M | 17.09M | 54.5M |
| EBITDA | (106.72M) | (58.24M) | (12.06M) | 88.8M | 178.43M |
| EBITDA Margin | -39.3% | -11.1% | -1.4% | 6.0% | 7.6% |
| Operating Income | (115.04M) | (68.7M) | (29.45M) | 61.9M | 105.61M |
| Operating Margin | -42.3% | -13.0% | -3.4% | 4.2% | 4.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.25M | 2.99M | 7.88M | 9.81M | 18.31M |
| Income Before Tax | (110.8M) | (65.71M) | (21.57M) | 71.71M | 123.92M |
| Pre-Tax Margin | -40.8% | -12.5% | -2.5% | 4.9% | 5.3% |
| Income Tax Expense | (3.14M) | (31K) | 1.98M | (54.33M) | (4.44M) |
| Net Income | (107.66M) | (65.68M) | (23.55M) | 126.04M | 128.37M |
| Net Margin | -39.6% | -12.5% | -2.7% | 8.5% | 5.5% |
| EPS (Basic) | (0.58) | (0.32) | (0.11) | 0.58 | 0.57 |
| EPS (Diluted) | (0.58) | (0.32) | (0.11) | 0.53 | 0.51 |
| Weighted Avg Shares | 186.78M | 204.52M | 209.34M | 215.94M | 224.96M |
| Weighted Avg Shares (Diluted) | 186.78M | 204.52M | 209.34M | 236.81M | 258.23M |
Hims & Hers Health, Inc.
NYSE:HIMS
Intrinsic Alpha fair value
Locked
Current Price
$17.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.